Radiation Therapy Planning Using Advanced Imaging – Pearls and Pitfalls
Sean P. Collins, MD, PhD, shares POSLUMA, a new PSMA-specific PET imaging agent approved in May 2023 for prostate cancer.
Read MoreSelect Page
Posted by Sean P. Collins MD, PhD | Dec 2024
Sean P. Collins, MD, PhD, shares POSLUMA, a new PSMA-specific PET imaging agent approved in May 2023 for prostate cancer.
Read MorePosted by Sean P. Collins MD, PhD | Jun 2024
Dr. Sean P. Collins discusses radiation therapy planning for prostate cancer, emphasizing the role of advanced imaging technologies. He underscores how these technologies enhance the precision of targeting cancerous tissues while minimizing radiation exposure to surrounding healthy tissues.
Dr. Collins elaborates on various advanced imaging modalities, including multiparametric MRI and PET/CT scans. He believes that integrating these imaging techniques into the radiation therapy planning process can result in more precise dose distributions, leading to better tumor control and fewer adverse effects.
Despite the clear advantages, Dr. Collins also addresses the potential pitfalls associated with advanced imaging in radiation therapy planning. Variability in image quality, the potential for imaging artifacts, and the necessity for specialized expertise in interpreting complex imaging data are addressed, as well as ways to mitigate these challenges.